awmsg logo



trastuzumab (Herceptin®)


Reference No. 1409

Publication date:
01/11/2012


Appraisal information

trastuzumab (Herceptin®) powder for concentrate for solution for infusion


Company: Roche Products Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 10/07/2012
AWMSG meeting date: 12/09/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2812
Ministerial ratification: 25/10/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion is recommended as an option for use within NHS Wales for the treatment of HER2 positive early breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download